Drug Profile


Latest Information Update: 12 Dec 2007

Price : $50

At a glance

  • Originator Beth Israel Deaconess Medical Center; Harvard Medical School
  • Developer ILEX Oncology Inc
  • Class Antineoplastics
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Cancer metastases

Most Recent Events

  • 12 Jun 2000 A preclinical study has been added to the Cancer pharmacodynamics section
  • 14 Mar 2000 Preclinical development for Cancer in USA (Unknown route)
  • 14 Mar 2000 Preclinical development for Cancer metastases in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top